Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.37 |
| ▸ | GLRB | P48167 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638845 | 1.00 | VCAM1 (0.48) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9158690 | 0.78 | HPN (0.44) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9680927 | 0.77 | HPN (0.41) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL9158352 | 0.76 | VCAM1 (0.46) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9314272 | 0.76 | MAOB (0.47) | LMNA | |
| SCHEMBL9330356 | 0.76 | HPN (0.47) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9847649 | 0.74 | VCAM1 (0.46) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9163349 | 0.73 | HPN (0.45) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL9328104 | 0.73 | HPN (0.52) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL8823307 | 0.73 | HPN (0.52) | VCAM1HPNMAPTALOX15SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074932-A1 | THE USE OF (S) - PANTOPRAZOLE MAGNESIUM FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| EP-0641569-A1 | ANTIPRURITIC | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | VCAM1 1110/4885GPR55 324/4885HPN 403/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | VCAM1 1110/4885GPR55 324/4885HPN 403/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | VCAM1 648/4885GPR55 2128/4885HPN 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.